Enhancing the Effects of Anti-Cancer Drug ICRF-193 (IMAGE)

Okinawa Institute of Science and Technology (OIST) Graduate University

Enhancing the Effects of Anti-Cancer Drug ICRF-193

Caption

Casein kinase II (CKII) phosphorylates DNA topoisomerase II (topo II), thus activating the ATPase domain of the enzyme (left). This activation cancels the effects of anti-cancer drug ICRF-193. If CKII activity is attenuated (right), the efficacy of ICRF-193 is rescued. The G0 Cell Unit demonstrated this mechanism in fission yeast, a simple model that could be used for anti-cancer drug screening.

Credit

OIST

Usage Restrictions

CC2.0 [attribution]

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.